ACN - 101321555 Australasian Human Research Ethics Consultancy Services Pty Ltd (AHRECS)

Resource Library

Research Ethics MonthlyAbout Us

ResourcesMedical research

Australasian Human Research Ethics Consultancy Services Pty Ltd (AHRECS)

Disgraced tracheal transplant surgeon is handed 16 month prison sentence in Italy (Papers: Michael Day | November 2019)0

Posted by Admin in on December 5, 2019
 

Disgraced surgeon Paolo Macchiarini, who faked research relating to dangerous and largely discredited tracheal transplants, has been handed a 16 month prison sentence in Italy for forging documents and abuse of office.

Macchiarini made headlines around the world after claiming a major breakthrough for patients with failing windpipes, by “seeding” an artificial scaffold with a patient’s own stem cells, to generate a functioning trachea.

But excitement at the prospect of a genuine medical advance turned to scandal when it emerged that Macchiarini had falsified results and misled hospital authorities regarding the health of those receiving the experimental procedures. The revelation prompted his research centre, the Karolinska Institute, to eventually disown his …

Day, M. (2019) Disgraced tracheal transplant surgeon is handed 16 month prison sentence in Italy. BMJ. 367:l6676. doi: 10.1136/bmj.l6676. No abstract available. PMID: 31767600
Publisher: https://www.bmj.com/content/367/bmj.l6676

Breakthrough Gene Therapy Clinical Trial is the World’s First That Aims to Reverse 20 Years of Aging in Humans – CISION (Osvaldo R. Martinez-Clark | November 2019)0

Posted by Admin in on November 28, 2019
 

This is the world’s first IRB-approved clinical trial aimed at reversing aging by at least 20 years; it is also the world’s most expensive pay-to-play trial with a one million price tag to enroll.

This isn’t a human research ethics vignette/scenario, but could very easily be used as the basis for a discussion with researchers, research ethics reviewers, research ethics advisers, or research office staff about:
.

  1. Pay-to-play clinical trials
  2. Appropriate recruitment materials
  3. The use of ethics approval as a sales tool
  4. The conduct of trials in another country

MANHATTAN, Kan., Nov. 21, 2019 /PRNewswire/ — Libella Gene Therapeutics, LLC (“Libella”) announces an institutional review board (IRB)-approved pay-to-play clinical trial in Colombia (South America) using gene therapy that aims to treat and ultimately cure aging. This could lead to Libella offering the world’s only treatment to cure and reverse aging by 20 years.
.

Under Libella’s pay-to-play model, trial participants will be enrolled in their country of origin after paying $1 million. Participants will travel to Colombia to sign their informed consent and to receive the Libella gene therapy under a strictly controlled hospital environment.
.

Traditionally, aging has been viewed as a natural process. This view has shifted, and now scientists believe that aging should be seen as a disease. The research in this field has led to the belief that the kingpin of aging in humans is the shortening of our telomeres.
.
Telomeres are the body’s biological clock. Every time a cell divides, telomeres shorten, and our cells become less efficient at dividing again. This is why we age. A significant number of scientific peer-reviewed studies have confirmed this. Some of these studies have shown actual age reversal in every way imaginable simply by lengthening telomeres.
.

Read the rest of this release

Examination of CIs in health and medical journals from 1976 to 2019: an observational study (Papers: Adrian Gerard Barnett, Jonathan D Wren | November 2019)0

Posted by Admin in on November 26, 2019
 

Abstract

Objectives
Previous research has shown clear biases in the distribution of published p values, with an excess below the 0.05 threshold due to a combination of p-hacking and publication bias. We aimed to examine the bias for statistical significance using published confidence intervals.

Design Observational study.

Setting
Papers published in Medline since 1976.

Participants
Over 968 000 confidence intervals extracted from abstracts and over 350 000 intervals extracted from the full-text.

Outcome measures
Cumulative distributions of lower and upper confidence interval limits for ratio estimates.

Results
We found an excess of statistically significant results with a glut of lower intervals just above one and upper intervals just below 1. These excesses have not improved in recent years. The excesses did not appear in a set of over 100 000 confidence intervals that were not subject to p-hacking or publication bias.

Conclusions
The huge excesses of published confidence intervals that are just below the statistically significant threshold are not statistically plausible. Large improvements in research practice are needed to provide more results that better reflect the truth.

Barnett, A.G., Wren, J.D. (2019)  Examination of CIs in health and medical journals from 1976 to 2019: an observational study. 

(Australia) Skin cancer doctor in hot water after papers retracted – The Age (Liam Mannix and Tom Cowie | November 2019)0

Posted by Admin in on November 24, 2019
 

For most, sailing the Mediterranean on a luxury cruise ship is a relaxing escape. But skin cancer expert Professor Anthony Dixon was working. And a storm was about to hit the credibility of his research.

Over the 12-day cruise, the professor spent nine hours teaching doctors and nurses how to recognise skin cancer. A prominent educator, Professor Dixon has trained dozens of health professionals in his methods, many of them on cruise ships.

But two of his journal articles were about to be retracted after complaints from other cancer experts that they contained factual errors. Such retractions are considered rare and necessary to prevent inaccurate information being available to other practitioners.

Read the rest of this news story

0